Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07231419 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
A Phase 3 study of Diabetic Peripheral Neuropathic Pain, sponsored by Vertex Pharmaceuticals Incorporated.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 734
- Enrollment target
- 20
- Study locations
NCT07231419 is a Phase 3 study of Diabetic Peripheral Neuropathic Pain that is actively recruiting participants, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 734 participants, above the 332-participant average among 7 other Diabetic Peripheral Neuropathic Pain trials with a reported enrollment target (121% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT07231419, a Phase 3 study of Diabetic Peripheral Neuropathic Pain, is actively recruiting participants, sponsored by Vertex Pharmaceuticals Incorporated.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 734 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine in participants with pain associated with diabetic peripheral neuropathy (DPN).
Conditions Studied
Interventions
- DRUG Suzetrigine
- DRUG Placebo (matched to SUZ)
Study Locations (20)
Florida
- Accel Research - Deland - DeLand
- Velocity Clinical Research - Hallandale Beach - Hallandale
- CNS Healthcare - Jacksonville - Jacksonville
- Health Awareness, Inc. - Jupiter - Jupiter
- 3Sync Research -Miami Lakes - Miami Lakes
- Health Awareness, Inc. - Port St. Lucie - Port Saint Lucie
California
- Eximia Research-CA, LLC - La Mesa
- Long Beach Research Institute - Long Beach
- Velocity Clinical Research -San Bernardino - San Bernardino
Missouri
- Healthcare Research Network - Hazelwood MO - Hazelwood
- AMR Kansas City - Kansas City
New York
- Brooklyn Clinical Research - Brooklyn
- Velocity Clinical Research - Syracuse - East Syracuse
Arizona
- Scottsdale Clinical Trials - Scottsdale
Colorado
- Paradigm Clinical Research - Wheat Ridge - Wheat Ridge
District of Columbia
- Velocity Clinical Research - Washington DC - Washington D.C.
Georgia
- Accel Research - Decatur - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 734 participants |
| Start Date | 2025-11-21 |
| Est. Completion | 2027-04-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07231419
The ClinicalTrials.gov registry entry for NCT07231419 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 734 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 332-participant average among 7 other Diabetic Peripheral Neuropathic Pain trials with a reported enrollment target (121% higher). The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Peripheral Neuropathic Pain appearing as the primary indexed condition, and to 2 interventions - of which Suzetrigine is the first listed.
NCT07231419 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT07231419 about?
NCT07231419 is a clinical study titled "Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy". The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine in participants with pain associated with diabetic peripheral neuropathy (DPN).
What is the current status of trial NCT07231419?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 734 participants. The study started on 2025-11-21. Estimated completion is 2027-04-06.
What conditions does trial NCT07231419 study?
This clinical trial studies the following conditions: Diabetic Peripheral Neuropathic Pain.
What interventions are being tested in trial NCT07231419?
The interventions under investigation include: Suzetrigine (DRUG), Placebo (matched to SUZ) (DRUG).
Who is sponsoring clinical trial NCT07231419?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07231419 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Peripheral Neuropathic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
RECRUITING · Phase 3
-
Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
ACTIVE NOT RECRUITING · Phase 3
-
MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP
RECRUITING · Phase 1
-
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
RECRUITING · Phase 2
-
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain
RECRUITING · Phase 2
-
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.